XW043P9
Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9
Introduce Glofitamab in Central Vein, Perc, New Tech 9
Axis Breakdown
Every ICD-10-PCS code is exactly seven characters, one per axis. Each character's meaning is defined by its position in the code.
| Position | Value | Meaning |
|---|---|---|
| 1 | SectionX | New Technology |
| 2 | Body SystemW | Anatomical Regions |
| 3 | Root Operation0 | Introduction Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products |
| 4 | Body Part4 | Central Vein |
| 5 | Approach3 | Percutaneous |
| 6 | Device / Substance / TechnologyP | Glofitamab Antineoplastic |
| 7 | New Technology Group9 | New Technology Group 9 |
Contextual Map
Every relationship of XW043P9 in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.
PCS table
- XW0[PCS table]
- [object Object] — Section: [object Object] [Section]: “[object Object]”
- [object Object] — Body System: [object Object] [Body System]: “[object Object]”
- [object Object] — Operation: [object Object] [Operation]: “[object Object]”
Nearest codes
- XW033P9 — Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9 [One axis away]
- XW043K9 — Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9 [One axis away]
- XW043PB — Introduction of Aztreonam-avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11 [One axis away]
- XW043Q9 — Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9 [One axis away]
- XW043R9 — Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9 [One axis away]
Change history
No changes recorded for this code — unchanged since the FY2026 (April) baseline of the change ledger.